Radiation nephropathy after bone marrow transplantation  by Cohen, Eric P.
Kidney International, Vol. 58 (2000), pp. 903–918
NEPHROLOGY FORUM
Radiation nephropathy after bone marrow transplantation
Principal discussant: Eric P. Cohen
Medical College of Wisconsin and Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, USA
Urinalysis showed 11 proteinuria, many red blood cells, one
epithelial cell cast, and 0 to 2 granular casts per low-power
field. A spot urine specimen showed 316 mg of protein per
gram of creatinine. A cyclosporine plasma level was 196 ng/mL
(parent plus metabolites).
The dose of cyclosporine was reduced, but the plasma creati-
nine rose to 2.1 mg/dL. A transvenous renal biopsy showed
extreme subendothelial expansion of the glomerular basement
membrane by electron-lucent amorphous material, no immune
deposits, and some mesangial expansion. The diagnosis of bone
marrow transplant glomerulopathy was made. Cyclosporine
was stopped.
Hyperkalemia and metabolic acidosis developed. Peripheral
renin activity was 2.9 ng/mL/h and the plasma aldosterone level
was 3.1 ng/dL when the plasma potassium was 4.6 mmol/L.
The hematocrit fell to 30% and erythropoietin was adminis-CASE PRESENTATION
tered. The plasma potassium rose to 6.9 mmol/L, with a simulta-
A 32-year-old woman was evaluated in the Nephrology neous plasma aldosterone of 1.7 ng/mL. Sodium polystyrene
Clinic at the Medical College of Wisconsin 10 years ago. Six sulfonate was given, and fludrocortisone was started. Restric-
months before, she had undergone an allogeneic bone marrow tion of dietary protein to less than 1 g/kg/day was advised but
transplant (BMT) from her sister as treatment for acute my- not achieved. Captopril was started but could not be continued
eloid leukemia (AML). Leg edema developed, and the plasma because of recurrent hyperkalemia. By four years after the
creatinine rose to 1.8 mg/dL; she was referred for evaluation. BMT, the plasma creatinine had reached 4.2 mg/dL.
Her medical history was remarkable for AML, which was Her blood pressure rose to 152/102 mm Hg. Diltiazem admin-
diagnosed 11 years ago. She initially was treated with ara-C istration was accompanied by edema. Atenolol and then doxa-
and daunorubicin. When in remission, she underwent BMT six zosin were used to control her blood pressure. The plasma
months after diagnosis from an HLA-matched sister. Before creatinine reached 6.7 mg/dL 21 months ago and an autogenous
the BMT, her plasma creatinine was 0.9 mg/dL. The BMT was arteriovenous fistula was placed in the left forearm. The plasma
immediately preceded by intravenous cyclophosphamide (2 g creatinine reached 9.9 mg/dL 15 months ago. Itching, nausea,
intravenously twice); cytosine arabinoside, 4.1 g intravenously and anorexia forced the start of chronic hemodialysis. She
for six doses; and total-body irradiation (TBI), given in nine currently remains on chronic hemodialysis and works 30 hours
fractions over three days, to a total dose of 14 Gy. A customized per week. She has declined renal transplantation.
shield reduced the dose to the kidneys by 15%.
Her course was complicated by a Hickman catheter infection
five months after the BMT, which was treated by catheter DISCUSSION
removal and a three-week course of vancomycin and ceftriax-
Dr. Eric P. Cohen (Associate Professor of Medicine,one. Her medications included acyclovir, ciprofloxacin, folic
Medical College of Wisconsin, and Senior Staff Physician,acid, progesterone, a multivitamin, once-weekly pentamidine,
Froedtert Hospital, Milwaukee, Wisconsin, USA): Radia-and cyclosporine, 60 mg daily. On examination one month
after diagnosis of the infection, she was afebrile, weighed 55.6 tion nephropathy is defined as renal injury caused by
kg, and she was 1.68 m tall. Her blood pressure was 114/80 ionizing radiation. In the past, the noun “nephritis” was
mm Hg sitting. She had ankle edema. No skin rash was present. used, but radiation nephropathy is not an inflammatory
condition, and the “itis” suffix thus is inappropriate. Clas-
sic radiation nephropathy occurs after sufficient irradia-The Nephrology Forum is funded in part by grants from Amgen,
tion of both kidneys. Just one decade after the discoveryIncorporated; Merck & Co., Incorporated; AstraZeneca LP; Dialysis
Clinic, Incorporated; and R & D Laboratories. of x-rays, clinicians already were aware of the potential
adverse effects of x-rays on renal function [1]. However,Key words: total-body irradiation, hemolytic-uremic syndrome, throm-
some of the early cases of “radiation nephritis” actuallybocytopenic purpura, endothelial injury, cyclosporine, ACE inhibitors,
mesangiolysis. might have been tumor lysis syndromes [2]. The first
case of radiation nephropathy was published in 1927 [3].Ó 2000 by the International Society of Nephrology
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Fig. 1. Occurrence of radiation nephropathy
according to time after irradiation, as defined
by Luxton and adapted from his data. One
hundred and thirty-seven men were irradiated
with 2230–3250 cGy in five weeks. X-ray was
given to treat seminoma and included the whole
of both kidneys. (Reproduced by permission
of the editor, Current Radiation Oncology,
Vol. 3, E. Arnold, Ltd, London, 1997.)
The present case illustrates its modern congener, bone occurred after a single dose of 1000 cGy TBI preceded
by cyclophosphamide. The authors stated that “ . . . TBI,marrow transplant (BMT) nephropathy.
probably in association with the radiomimetic action of
Clinical features cyclophosphamide, may result in radiation nephritis in
BMT recipients” (abstract; Kamil et al, Kidney IntAt the onset, I should emphasize that the BMT ne-
14:713, 1978).phropathy syndrome is not the same as the acute renal
The published cases of BMT nephropathy now num-failure that can occur after BMT. As reviewed by Zager
ber over 100. Our own center has had more than 40in an earlier Nephrology Forum, acute renal failure
cases in adults and additional cases in children. The usewithin the first 30 days after BMT is associated with
of BMT is increasing steadily, and additional cases areneutropenia, sepsis, the use of antibiotics, and liver fail-
to be expected. Worldwide, more than 20,000 BMTs areure [4], and can occur in 25% or more of BMT patients.
performed each year. Bone marrow transplant nephrop-This early acute renal failure does not appear to be
athy is specifically relevant for programs that use TBIrelated to the later development of BMT nephropathy.
in their conditioning regimens, although one case of his-The dose of radiation to which the kidneys were ex-
tologically proven BMT nephropathy has been describedposed in today’s patient, 11.9 Gy, or 1190 cGy (rads), is
in a patient who was exposed to multiple cytotoxic che-lower than the doses traditionally associated with radia-
motherapy but not to renal irradiation [9]. By actuarialtion nephropathy, which are usually greater than 2000
statistics, as many as 20% of BMT patients develop latecGy. Almost fifty years ago, Luxton identified 2500 rads
chronic renal failure [10].as the threshold dose for radiation nephropathy, but this
Luxton differentiated four variants of radiation ne-dose was for irradiation spread out in multiple fractions
phropathy (Fig. 1). Of these, so-called acute radiationover 25 to 30 days [5]. The discrepancy between the
nephritis most closely corresponds to BMT nephropathykidney irradiation dose in this patient and that which
in its chronology, because both have their clinical onsetLuxton identified as a threshold dose probably can be
between 6 and 12 months after the initial irradiation.explained by the effects of fractionation, time, and effects
The onset of acute radiation nephropathy is only acuteof cytotoxic chemotherapy. In laboratory rodents, the
relative to the other variants. In fact, radiation nephropa-single doses of x-ray that cause radiation nephropathy
thy is a late phenomenon in a day-to-day clinical sense,do not cause radiation nephropathy when fractionated
occurring months or years after the exposure. In classicalinto multiple, separated doses [6]. The increasing “toler-
radiation biology, the kidney is a late-responding tissueance” with increasing fractionation is likely due to repair
compared to, for instance, bone marrow or the gastroin-of sublethal radiation damage during the time between
testinal epithelium. Generally, late-responding tissuesfractional doses. The total-body irradiation (TBI) that
have slower cell turnover rates than do early-respondingis given just before clinical BMT is administered in nine
tissues (the so-called law of Bergonie´ and Tribondeau).fractions over three days; this schedule might not allow
Radiation kills cells by damaging DNA. Cell death bysufficient time for repair of radiation injury to the kidney.
radiation can occur by apoptosis but more likely cellIn addition, the TBI given for BMT is preceded by cyto-
toxic chemotherapy, that is, the previous cancer treat- death is delayed until the cell divides. Normal renal tissue
has low mitotic rates, so it should follow that expressionment and the concurrent cytotoxic chemotherapy given
as part of pre-BMT “conditioning.” This chemo-irradia- of renal injury after radiation is delayed. The azotemia
and edema that occurred in today’s patient at about sixtion conditioning is necessary both for ablation of malig-
nant cells and for immunosuppression of the host [7]. months after TBI happened at a typical time for the
onset of BMT nephropathy, which on average is eightPrevious cytotoxic chemotherapy potentiates the effects
of ionizing radiation [8]. Indeed, the very first case of months after TBI [11]. Oyama et al documented a latent
period of eight years for chronic renal failure after BMT,BMT nephropathy, reported by Kamil et al in 1978,
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Fig. 2. Prevalence of hypertension after bone
marrow transplant (BMT), shown as a frac-
tion, and as a function of the degree of simulta-
neous azotemia. These data were obtained in
1999, are cross sectional in nature, and are
for adults. Hypertension is defined as a blood
pressure of 140/90 mm Hg or use of antihyper-
tensive agents. The fractional prevalence is
shown as a function of the range of plasma
creatinine for each of six groups. The average
time of follow-up in each group ranges widely,
from 1 to 45 months. There is no significant
difference in age between the groups. When
the plasma creatinine is in the normal range,
that is, less than 1.1 mg/dL, there does not
appear to be a disproportionately high preva-
lence of hypertension compared to the preva-
lence that exists in a normal population of the
same age.
a timing possibly analogous to that for classic chronic rine does not appear to exacerbate experimental radia-
tion nephropathy [16].radiation nephropathy [12].
At initial evaluation 10 years ago, today’s patient wasIn the present patient as well as in other reported
not hypertensive, although later her blood pressure didcases of BMT nephropathy, again we find a latent period
rise and she required antihypertensive treatment. Thisof many months from the initial TBI to the development
course is atypical for most BMT nephropathy cases, inof BMT nephropathy. A single clinical study of 16 adult
which hypertension usually is present when the patientpatients undergoing TBI-based BMT showed increased
is first seen. Hypertension also is a typical feature ofglomerular filtration rate and renal blood flow within four
classic radiation nephropathy and has been ascribed todays of completion of the TBI [13]. The long-term evolu-
vascular injury caused by radiation [17]. In Luxton’s stud-tion of these patients was not described, however. It is
ies of radiation nephropathy, hypertension also coulddifficult to establish a relationship between these early
occur in the absence of renal failure. We attempted tohemodynamic changes and the later development of
identify isolated hypertension in adult BMT patients whochronic renal failure, especially when only a minority of
were under long-term follow-up care at our center. Allrenally irradiated subjects develop chronic renal failure.
but 10 records of 267 living adult BMT patients wereToday’s patient received cyclosporine concurrently
identified. The type of transplant, time of follow-up, pa-with TBI. One could argue that some of her azotemia
tient age, renal function (as plasma creatinine), and bloodcould be blamed on the cyclosporine, yet her plasma
pressure were recorded for the most recent follow-upcreatinine rose, rather than fell, when the drug was dis-
visit. This study showed a close correlation between de-continued. In addition, the syndrome of BMT nephropa-
gree of azotemia and prevalence of hypertension (Fig. 2).thy is well documented in BMT patients who have never
A similar correlation was found in the subgroup receiv-
received cyclosporine [14]. Nevertheless, some renal in-
ing allogeneic BMT (N 5 143), a noteworthy finding
jury syndromes after BMT are likely related to cyclo- because the allogeneic BMT patients almost always have
sporine use. Shulman et al first described a hemolytic- had TBI. Transformation of the plasma creatinine level
uremic-like syndrome that occurred within the first few to calculated creatinine clearance by use of the Cockcroft
weeks after BMT [15]. The doses of cyclosporine used and Gault formula did not change this relationship,
in that report were 12.5 to 15.0 mg/kg body weight/day, which is very similar to that for chronic renal failure
doses higher than those currently used. Some similarities in general. Indeed, in data gathered on 1795 subjects
exist between the early cyclosporine syndrome and BMT participating in the Modification of Diet in Renal Dis-
nephropathy. Indeed, the more severe variants of BMT ease (MDRD) trial, for instance, as the iothalamate-
nephropathy look clinically like hemolytic-uremic syn- calculated glomerular filtration rate (GFR) decreased,
drome or thrombotic thrombocytopenic purpura, in that the prevalence of hypertension increased, reaching al-
these variants are accompanied by hemolysis, thrombo- most 100% at a GFR of 10 mL/min [18]. It thus is not
surprising that as the renal function in today’s patientcytopenia, and seizures. But in laboratory rats, cyclospo-
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Fig. 3. Photomicrograph by light microscopy of a renal biopsy specimen in a typical case of BMT nephropathy. There is mesangiolysis (asterisk)
and extreme widening of the space between endothelium and glomerular basement membrane (arrow). The tubular epithelium is intact, but the
tubules are separated by an expanded interstitium (PAS stain; magnification 3250).
declined, her blood pressure rose. In general, our data tial causes of renal disease such as postinfectious glomer-
ulonephritis (from the infected Hickman catheter) ordo not indicate that hypertension occurs independently
of azotemia after renal irradiation. That conclusion could cyclosporine toxicity.
At least eight patients with BMT nephropathy at ourchange with longer follow-up or different schedules of
irradiation. center have had episodic hyperkalemia without other
causes such as urinary tract obstruction, use of nonsteroi-Our initial description of this syndrome did not include
histopathologic evidence [19]. We relied on a clinical dal anti-inflammatory medicines, or cyclosporine toxic-
ity. Four have had hypoaldosteronism and, like the presentdefinition: azotemia, hypertension, and anemia occurring
100 days or more after BMT in the absence of another patient, have been treated with supplemental mineralo-
corticoid (fludrocortisone). Tubular defects are not de-nephrotoxin. Of our 19 original patients, 9 underwent
renal biopsy. In each biopsy, both the light and electron scribed in classic radiation nephropathy, although the
multicellular nature of experimental radiation nephropa-microscopic appearances were striking and typical. We
noted mesangiolysis as well as loss of endothelial cells thy could account for deficient tubular function in either
classic radiation nephropathy or BMT nephropathy.with subendothelial expansion and capillary loop occlusion
(Fig. 3). Ultrastructural examination showed endothelial The anemia of radiation nephropathy as well as BMT
nephropathy is disproportionately worse than would becell injury and extreme subendothelial cell widening of
the glomerular basement membrane by an amorphous expected for the degree of azotemia [22]. Hemolysis
might be responsible for this discrepancy, especially inmaterial that appeared to extend the lamina rara interna
(Fig. 4). This electron microscopic appearance is very the more severe cases of BMT nephropathy that are
reminiscent of hemolytic-uremic syndrome. The role ofsimilar to that of typical radiation nephropathy [20, 21].
Its presence in today’s patient helps rule out other poten- erythropoietin deficiency cannot be ignored, however,
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Fig. 4. Photomicrograph by electron micros-
copy of a renal biopsy specimen in a typical
case of BMT nephropathy. Endothelial swell-
ing and irregularity are present. There is ex-
treme widening of the space between endothe-
lium and glomerular basement membrane
(asterisk). No immune deposits are apparent,
and the glomerular basement membrane itself
does not appear abnormal.
patients in our center have received treatment, and we
have emphasized control of blood pressure. Our goal
has been to maintain the outpatient, sitting, mean arterial
blood pressure at 100 mm Hg or less [10]. This therapeu-
tic goal might be responsible for the biphasic nature of
the 100/creatinine graphs that are so typical of BMT
nephropathy, the slower phase representing a slowing
of progression because of the use of antihypertensive
medications. Alternatively, the rapid phase might repre-
sent the active injury phase, and the plateau part of the
curve could represent inactive disease. We have insuffi-
cient data to decide between these possibilities.
In the past decade, angiotensin-converting enzyme
(ACE) inhibitors have repeatedly been shown to slow
the loss of renal function in diabetic and nondiabetic
Fig. 5. Evolution of renal function in the patient presented, shown
renal diseases [23, 24], even when the urinary proteinhere as 100/plasma creatinine versus time. There is a biphasic pattern,
with an initial rapid decline, then a plateau that culminated in end- excretion is in a non-nephrotic range [25]. This apparent
stage renal disease nine years after bone marrow transplantation. benefit of ACE inhibitors over other antihypertensive
agents probably is much less when the blood pressure is
well controlled. Nonetheless, we have attempted to use
ACE inhibitors or angiotensin II receptor blockers when-because blood erythropoietin levels have been low when
ever possible in BMT nephropathy, and we recommendmeasured, and because erythropoietin therapy has been
their use in radiation nephropathy generally [22]. Thisuniformly successful in raising the hematocrit in patients
preference is influenced by our own laboratory data,with BMT nephropathy.
which show significant and impressive benefit of ACEThe progressive loss of renal function in today’s pa-
inhibitors or angiotensin II antagonism in experimentaltient is shown in Figure 5. The evolution of BMT ne-
radiation nephropathy; I will return to this topic. We alsophropathy is usually biphasic, with an initially rapid loss
are influenced by the favorable report from Antignac etof renal function, followed by a slower phase or even
al, who reported improvement of renal function in threelong-term stabilization. The rapid phase has an estimated
of seven children with BMT nephropathy treated withrate of loss of GFR that is many times greater than
enalapril [26].that for other chronic renal diseases, and its rapidity
Progression to end-stage renal disease (ESRD) cancorrelates with the nadir of the platelet count and the
peak of the plasma LDH rise in these patients [11]. All occur despite optimal care in patients with chronic renal
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failure; ESRD has occurred in a dozen patients with scopic studies in mice showed a similar sequence of glo-
merular injury preceding the tubular alterations [35].BMT nephropathy at our center and has been docu-
mented at other centers as well [12, 14, 27–30]. Although Other workers have emphasized vascular injury as an
important determinant of late functional loss [36–38].today’s patient is currently stable on chronic hemodialy-
sis, our overall impression has been that ESRD after These and other studies have prompted the two tradi-
tional hypotheses regarding the pathogenesis of radia-BMT augurs poorly for a lengthy survival on dialysis.
A case-control study published in 1998 documents this tion nephropathy. The first holds that vascular injury is
the key event in radiation nephropathy and that its extentimpression [27]. When patients undergo chronic dialysis
after BMT, their survival is poor compared with either governs outcome [36]. The second holds that radiation
injury to parenchymal cells, specifically the tubular epi-nondiabetic or diabetic age-matched patients on dialysis
who have not had a BMT. thelium, is the critical feature of radiation nephropathy,
and that the extent of subsequent cell depopulation de-The possibility of renal transplantation in such patients
was first discussed in 1991 by Sayegh et al [31]. That termines the functional outcome [39]. The vascular injury
hypothesis might help us understand the hypertensionreport describes two patients, each of whom received
an allogeneic BMT from a sibling and then developed of radiation nephropathy, but it does not easily explain
the characteristic and not merely ischemic glomerularchronic renal failure. After a period on dialysis, each
received a renal transplant from the marrow donor and lesions. It also ignores the fact that renal tubular epithelial
cells have an in vitro radiosensitivity that approximatesrequired no immunosuppression to maintain function of
the renal graft. These patients likely were immunotoler- that of cells in acutely responding non-renal tissues.
The tubular-cell-depletion hypothesis has been ex-ant of the transplanted kidney. Since then, more than a
dozen cases of renal transplantation for ESRD after plored by an analysis of radiosensitivity of renal tubu-
lar epithelial cells. The so-called D0 describes the dose-BMT have been reported [30, 32]. Among the six from
our center, three received a kidney from the same sibling response curve of cell survival after irradiation. It is the
dose, in centigray, that reduces the surviving fraction ofwho donated the marrow. In such special cases, immuno-
suppression after renal transplantation is not necessary. irradiated cells to 37% of the starting value. Bone mar-
row stem cells have a D0 of about 100 cGy, and thatWhen the kidney is foreign to the host marrow, immuno-
suppression is needed, although perhaps at only 50% of of renal tubular cells is 150 cGy. Cellular damage to
irradiated renal cells is thus possible for doses of irradia-the usual drug doses, because subjects who have had a
BMT might not ever have complete immunologic recon- tion that will also cause ablation of the bone marrow.
That the marrow responds to radiation much earlier thanstitution [33].
the kidney does is more a function of mitotic rate than
Experimental radiation nephropathy of intrinsic cellular radiosensitivity. Thus, the tubular
cell depletion hypothesis at least partially explains theRadiation nephropathy, clinical or experimental, is an
example of radiation injury to normal tissue. Generally, latency of radiation nephropathy. But by its very nature,
radiation reaches all components of the irradiated organ.the curative abilities of therapeutic irradiation in cancer
treatment are limited not only by the radiosensitivity of I believe that it is simplistic to conceive of radiation
nephropathy as specifically dependent on either vascularthe cancer cells, but also by the response of the sur-
rounding normal tissue. In clinical BMT, the kidney is or renal tubular injury.
Debates about the mechanism of radiation nephropa-a key limiting organ that restricts application of chemora-
diotherapy (Safwat et al, Eur J Cancer 29A:929, 1993). thy, in particular concerning the target tissue or cell that
is most important, occupied much of the literature onThese facts have prompted the study of radiation ne-
phropathy in experimental animals, both to provide in- the subject in the 1970s and 1980s. There were few efforts
at treating radiation nephropathy—after all, the classicsights into the specific problem and as a paradigm for
normal tissue radiation injury. view was that radiation nephropathy, like most late radi-
ation injuries, was untreatable [36]. The resurgence ofMorphologic studies of radiation nephropathy have
documented injury to blood vessels, glomeruli, tubular radiation nephropathy in the form of clinical BMT ne-
phropathy was part of the reason for the creation, byepithelium, and interstitium. Recent ultrastructural stud-
ies indicate that glomerular endothelium is an early site Moulder and colleagues, of a radiation nephropathy
model in rats using total-body irradiation followed byof visible injury, occurring at three weeks after 9.8 Gy
single-dose kidney irradiation in a porcine model [34]. bone marrow transplantation [40]. The bone marrow
transplant from a syngeneic littermate prevents deathIn those studies, endothelial disruption and leukocyte
adherence were followed by subendothelial expansion from bone marrow failure. In this model, single-fraction
1000 cGy or six-fraction 1700 cGy (over three days)with electron-lucent material. The endothelium appeared
very much like that in human BMT nephropathy. Tubu- causes renal histologic and functional injury in 50% of
irradiated rats within three months after irradiation. Thelar degeneration and atrophy occurred later. Light-micro-
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use of syngeneic rats avoids the superimposition of graft-
versus-host-disease, and use of a barrier facility obviates
common infections and thereby avoids pulmonary death.
Thus, in this model, survival of the irradiated rat is a
direct function of the degree of renal injury. Earlier
workers had documented similar effects of renal irradia-
tion in murine models, but the effects occurred at much
longer latencies, thus making those models less practical.
The WAG/Rij rat model used by Moulder and colleagues
is highly suited for analysis of radiation nephropathy.
Moreover, its similarity to clinical BMT nephropathy
implies that lessons derived from its study can be readily
applied to patient care.
In this model, significant proteinuria occurs by six
weeks after TBI. The creatinine clearance is significantly
lower than that in unirradiated normal rats by 9 weeks
after TBI, and significant hypertension occurs by 17
weeks after TBI [41]. Histologically, radiation nephropa-
thy in our model is very similar to the human lesion [42].
Early studies of this model confirmed that cytotoxic
chemotherapeutic drugs can exacerbate radiation ne-
phropathy [43]. Survival of irradiated rats was signifi-
cantly shortened if cis-platinum or BCNU was given to
the animals three months before 17 Gy TBI plus BMT.
These data support the idea that previous chemotherapy
contributes to the pathogenesis of BMT nephropathy.
Efforts at treating radiation nephropathy were non-
existent until studies using captopril were started in the Fig. 6. Time course of renal function parameters after 17 Gy TBI for
early 1990s. One publication had documented that capto- rats given captopril (s), enalapril (e), verapamil (h), or no drug (d)
before TBI. Data are shown as geometric means with 95% confidencepril could attenuate the hemodynamic response to renal
intervals. The 95% confidence intervals for normal control (no drugsirradiation over the short term, but this study was limited
and no TBI) animals are shown as hatched areas. (Reproduced by
to 9 animals and a 12-week follow-up [44]. By 1990, the permission of the editor of the Journal of Laboratory and Clinical
Medicine.)work of Ward and colleagues had shown the preventive
benefit of ACE inhibitors in a radiation pneumonitis
model [45, 46]. Coupled with the then rapidly burgeoning
body of work on the benefit of ACE inhibitors in experi-
failure and death within nine months of irradiation. Wemental renal disease, these data set the stage for testing
gave captopril to one-half of the irradiated rats startingACE inhibitors in experimental nephropathy. The ratio-
at the six-month time point, when renal injury level wasnale for this approach is obvious in retrospect, but in
well established. The decline in renal function slowedthe late 1980s, treatment of radiation nephropathy was
significantly, and survival in the captopril-treated as op-directed toward symptoms alone. On the clinical level, a
posed to the irradiated, no-drug rats was twofold greater.major text stated in 1987 that “. . . there is little that
These results were reproduced with the non-thiol ACEcan be done to alter its progression . . .” [47]. On the
inhibitor enalapril, and with captopril in a TBI model [50].experimental side, no publication had addressed treat-
We obtained even more impressive results using cap-ment. Radioprotectors such as WR-2721 (s-2(3-amino-
topril or enalapril in a preventive fashion, that is, frompropylamino)-ethyl phosphorothioic acid) had been
the time of irradiation onward (Fig. 6) [41]. Similar re-shown to prevent experimental radiation nephropathy
sults were obtained in a local kidney irradiation model[48], but such agents need to be “on board” at the time
by three other groups [51–53]. Other antihypertensiveof irradiation and are likely to have no benefit in the
agents, including hydrochlorothiazide or verapamil, weretreatment of established radiation nephropathy.
ineffective in preventing radiation nephropathy. At 500Our first studies of treatment of experimental radia-
mg/L in the drinking water, the estimated daily dose oftion nephropathy were done in a local kidney irradiation
captopril to the laboratory rat is two or three times highermodel using 15 to 27 Gy in 12 fractions [49]. Azotemia
than that which humans typically receive (corrected forand proteinuria occur within six months after irradiation
in this model, which, if left untreated, will lead to renal body surface area). It was therefore important to test
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Fig. 7. Representative histologic specimens are shown for rats sacrificed 33 weeks after 17 Gy TBI plus BMT (3140; periodic acid-Schiff). (A)
Specimen from normal control, showing normal renal microarchitecture. This animal had a BUN of 21 mg/dL, a urine protein/urine creatinine
(UP/UC) ratio of 2.6, and a systolic blood pressure of 127 mm Hg. (B) Specimen from an animal treated with 17 Gy TBI plus BMT, showing
arteriolar (a) and glomerular (b) capillary thrombosis, mesangial sclerosis (c), capillary loop collapse (d), and tubular atrophy (e). Prior to sacrifice,
this animal had a BUN of 75 mg/dL, a UP/UC ratio of 13, and a blood pressure of 198 mm Hg. (C) Specimen from an animal with 17 Gy TBI
plus BMT and the ACE inhibitor captopril showing mesangial sclerosis in all glomeruli and segmental mesangiolysis with microaneurysm formation
(arrow) in one glomerulus. Prior to sacrifice, this animal had a BUN of 42 mg/dL, a UP/UC ratio of 1.8, and a systolic blood pressure of 137
mm Hg. (D) Specimen from an animal treated with 17 Gy TBI plus BMT and the Ang II receptor antagonist L-158,809 showing no glomerular
alteration and a single atrophic tubule (arrow). Prior to sacrifice, this animal had a BUN of 26 mg/dL, a UP/UC ratio of 0.80, and a systolic blood
pressure of 104 mm Hg. (Reproduced by permission of the editor of Radiation Research.)
whether smaller doses of captopril were effective. We phropathy. This impression is supported by recent data
in our model showing a time-specific worsening of exper-reduced the dose of captopril in increments to eightfold
less, that is, to 62.5 mg/L in the drinking water. At this imental radiation nephropathy by infusion of Ang II [55].
When we infused Ang II at 400 ng/kg/min intraperitone-dose, there was still long-term preservation of renal func-
tion after 17 Gy TBI, yet without significant prevention ally, it exacerbated radiation nephropathy when infused
between four and eight weeks after TBI. There was noof proteinuria, and with only modest amelioration of
hypertension. Further studies showed impressive preven- such worsening when the same dose of Ang II was in-
fused from zero to four weeks after TBI, and also notive efficacy of the angiotensin type-1 receptor blocker
L-158,809 [54]. In these studies, when captopril, 500 effect at 200 ng/kg/min. We did find a trend towards
higher blood pressure in the irradiated rats infused withmg/L, was compared to L-158,809, 20 mg/L, in the drink-
ing water, the angiotensin II (Ang II) antagonist pro- Ang II at 400 ng/kg/min from four to eight weeks when
compared with irradiated noninfused rats (P 5 0.08).vided somewhat better functional and histologic protec-
tion compared with captopril (Fig. 7). Blood pressure It is not surprising that Ang II exacerbates radiation
nephropathy, but that it only does so at a particularwas lower in the L-158,809-treated rats, so the drugs
were not given at blood pressure-equivalent doses. interval after irradiation is striking.
In spite of our enthusiasm for the role of the renin-Together, these data point to a role for the renin-
angiotensin system in the pathogenesis of radiation ne- angiotensin system, Ang II does not by itself cause radia-
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tion nephropathy. Johnson and colleagues showed that the overlapping 4- to 8-week interval for exacerbation
of radiation nephropathy by Ang II led us to examinein normal rats, Ang II infusion (200 ng/min) for two
weeks caused vascular and tubulointerstitial injury to that interval more closely. Recent cell kinetic studies
by Robbins and colleagues showed that glomerular andthe kidneys but with little glomerular injury [56]. We
infused Ang II into normal, unirradiated rats at 800 ng/ tubular cells proliferated in that same interval after
9.8 Gy single-fraction kidney irradiation in a porcinekg/min for eight weeks. We found medullary fibrosis,
but neither lasting functional injury nor signs typical of model [63]. These studies used bromodeoxyuridine in
situ labeling, and flow cytometry of kidney cell suspen-radiation nephropathy [55].
Earlier histologic studies of radiation nephropathy had sions. Radiation-induced tubular cell proliferation has
been documented by others in a mouse model [64]. Wesupported the idea of an activated renin-Ang II system
[57]. We therefore measured blood levels of renin and have confirmed a tubular and glomerular enhancement
of immunostaining with the proliferating cell nuclearAng II in irradiated rats but found no change from con-
trol, unirradiated rats (abstract; Moulder JE et al, Proc antigen (PCNA) in our 17 Gy TBI/BMT model, and we
found that this enhanced PCNA staining is completely11th Int Cong Rad Res 1:156, 1999). A similar lack of
change in blood renin was reported in a porcine model prevented by use of L-158,809 in the drinking water of
irradiated rats (abstract; Moulder et al, Proc 11th Intby Robbins and colleagues [58]. These data are reminis-
cent of those found in the remnant kidney model [59], Cong Rad Res 1:156, 1999). The tubular PCNA staining
increased significantly by 3 weeks after irradiation andin which intrarenal activation of the renin Ang II system
can occur without an elevation in the systemic plasma preceded the rise in glomerular PCNA staining. The
3-week time point precedes proteinuria, hypertension,renin level. Further investigation of the intrarenal renin–
Ang II system in radiation nephropathy might clarify and azotemia in this model. The prevention of the rise in
PCNA staining by the Ang II blocker and the concurrentwhether or not it is activated.
We performed additional studies to address whether functional benefit of the Ang II blocker support the
idea that the tubular cell proliferation is mechanisticallyACE inhibitors act as radioprotectors or in an alternative
fashion. Radioprotectors such as WR-2721, which scav- important in the expression of radiation nephropathy.
The cause of the cellular proliferation, glomerular orenge oxygen radicals, need to be present at the time of
irradiation. However, captopril could be started three tubular, remains unexplained.
weeks after TBI, and if continued thereafter, would be as
Cellular eventseffective as when it was given from the time of irradiation
[60]. This finding argues strongly against a “radioprotec- As I noted earlier, morphologic studies show that en-
dothelial injury is an early event in radiation nephropa-tive” action of captopril, and favors an action of this
drug on a process set in motion by the irradiation. It thy [34]. In vitro studies of human umbilical vein endo-
thelial cells showed acute release of von Willebrandalso implies that in clinical use, for prevention of normal
tissue injury, ACE inhibitors need not be present at the factor after 20 Gy irradiation; this finding might help
explain the concurrent increase of platelet adhesion intime of irradiation.
These observations and other studies showing a bene- the same studies [65]. These in vitro data also might
explain the beneficial preventive effect of aspirin in afit for brief courses of captopril, given only between 3
and 10 weeks after irradiation [61], support the notion murine model of radiation nephropathy [66]. Studies of
irradiated rabbit aorta have shown that as little as 5 Gythat in radiation nephropathy, the initial events at the
time of irradiation do not result in unavoidable, inexora- (in a single dose) depresses the subsequent capacity of
the blood vessel wall to generate prostacyclin, alone orble organ failure. Rather, a cascade of events might be
set in motion upon which beneficial intervention is possi- after stimulation by PDGF [67]. The vascular and glo-
merular thromboses described in radiation nephropathyble. In radiation nephropathy, the benefits are less azote-
mia, lower blood pressure, and greater survival when [35, 68] could well derive from these cellular changes
that tend to favor coagulation. Recently, Oikawa et alcaptopril is used from 3 to 10 weeks after irradiation.
One can speculate that other agents would exert similar provided additional evidence for the role of the clotting
system by demonstrating increased renal plasminogenbenefits when used at other intervals after irradiation.
Studies of the renin-angiotensin system have identified activator inhibitor-1 (PAI-1) mRNA in a 12 Gy single-
dose radiation nephropathy model, and the attenuationa hormonal system that is important in radiation ne-
phropathy, but they have not identified the tissue or cell of that increase by either ACE inhibitors or an Ang II-
receptor blocker [53]. The increased PAI-1 was localizedthat is most important. Angiotensin II is generated in
blood vessels, glomeruli, and proximal tubular epithelial to the glomerulus. Increased PAI-1 could not only pre-
vent fibrinolysis, but it also might promote fibrosis viacells of the kidney [62], any one or all of which could be
involved in the pathogenesis of radiation nephropathy. attenuation of plasmin-mediated matrix degradation.
This concept of radiation nephropathy might explainThe 3- to 10-week interval for captopril benefit and
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glomerular scarring, but it is less able to account for Let me offer one hypothetical mechanism for radiation
nephropathy (Fig. 8). Glomerular injury might lead totubular proliferation or interstitial scarring.
Attachment of neutrophils to the injured endothelium egress of pathologic mediators into the urinary space,
and this leakage might produce parenchymal fibrosis ifis also a salient early feature of radiation nephropathy
[34]. Eldor et al have shown a dose- and time-related tubular denudation is present. This mechanism relies on
injury to more than one renal tissue type. It fits nicelyrelease of neutrophil chemotactic activity after in vitro
irradiation of endothelial cell monolayers [69]. This sub- with the notion that proteinuria plays a role in progres-
sive renal injury [74]. It also is compatible with the ideastance is a product of the lipoxygenase pathway but has
not been definitively identified. of “toxic ultrafiltrate” of pro-fibrotic cytokines that
might leak from an injured glomerulus, only to damageMesangial cells also participate in radiation nephropa-
thy. Mesangiolysis is a prominent feature of clinical BMT the downstream tubule [75]. If the tubular epithelium is
prevented from proliferating, for instance, with Ang IInephropathy [11, 68]. The mesangium not only expands
but also seems to disintegrate. Mesangiolysis also occurs blockade, then perhaps the toxic ultrafiltrate is less apt
to cause tubulointerstitial and whole-organ injury. Simul-in rat radiation nephropathy. By contrast, mesangial cells
are activated in porcine radiation nephropathy, with ex- taneously, the same Ang II blockade would diminish
glomerular injury and lessen the production of toxic ul-pression of alpha smooth muscle actin and cellular prolif-
eration [70]. Glomerular scarring ensues in all models. trafiltrate. In any case, present or future therapies for
radiation nephropathy might be more successful if di-The occurrence of later mesangial scarring raises the
question of what mediators are involved. In vitro studies rected at more than one mechanism of injury.
Given these experimental data, at our center we nowof irradiated rat mesangial cells show a dose-related in-
crease in TGF-b1 mRNA at 24 and 48 hours after 5 to approach the care of our patients with BMT nephropathy
as follows. First, we strive for excellent control of the20 Gy irradiation [71]. Yet subsequent studies by the
same group failed to show an increase in total TGF-b1 blood pressure, aiming for a sitting mean arterial blood
protein under the same conditions [72]. In a porcine pressure of 100 mm Hg or less. Second, ACE inhibitors
model, glomerular TGF-b1 expression is a late and unim- are used, or Ang II blockers, to antagonize the renin-
pressive phenomenon (compared to its tubular epithelial angiotensin system. Specific dose recommendations are
expression); thus, TGF-b1 might not contribute signifi- not established. By this approach, we are not only reduc-
cantly to glomerular scarring [70]. Additional data show ing the hypertensive contribution to chronic renal failure
acute increases in tissue inhibitor of metalloprotease but also possibly interfering with renin-angiotensin me-
(TIMP) secretion by irradiated rat mesangial cells [72]. diated pathways of injury in radiation nephropathy. It
This occurrence could be important in initiating mesan- is likely, however, that the renin-angiotensin system is
gial scarring [72]. important in the earlier phases rather than in the estab-
The classic interpretation of radiation-induced cell lished phase of radiation or BMT nephropathy. This
death is that it occurs when the injured cell or its progeny realization, which is based on the experimental “inter-
attempt to divide, only to die in mitosis [39]. The renal val” studies [55, 61], has motivated us to start a clinical
tubular epithelium is sensitive to irradiation [39]. That trial using captopril in a preventive manner in patients
is, after doses not dissimilar to those that damage other undergoing BMT at our center. Specifically, in adults
cell types, renal tubular epithelial cells also eventually who have undergone TBI-based BMT, captopril (or pla-
die. The death of some, but not all, cells can provoke cebo) is started at the time of engraftment of the new
others to proliferate and attempt to “fill the gaps.” This marrow, which is about three weeks after the TBI/BMT.
in turn can provoke the death of more cells because of Captopril (or placebo) is then continued for one year.
their radiation-damaged DNA. But recent data show Outcomes to be studied include the BMT nephropathy
early apoptosis in irradiated rat kidneys, within the first syndrome as well as renal function in all subjects. This
day after 5 Gy single-dose TBI [73]. The later prolifera- preventive use of captopril might prove to be even more
tive response in tubular epithelium—at 3 weeks in both effective than its therapeutic use.
rat and pig—might then be a secondary phenomenon, a
reaction to cell depletion caused by apoptosis.
QUESTIONS AND ANSWERSThe importance of tubular epithelial cell loss in radia-
Dr. John T. Harrington (Dean, Tufts Universitytion nephropathy is obscure. If radiation nephropathy
School of Medicine, Boston, Massachusetts): I think Iwere merely tubular cell depletion, it might cause a slow-
understand the delay between radiation and overt radia-motion acute tubular necrosis or even a syndrome similar
tion nephropathy, but it is still not clear to me whyto cis-platinum nephrotoxicity. Glomerular injury also
virtually nothing happens, in effect, from zero to four ormust be taken into account, because it undeniably is
six weeks. Perhaps you could amplify that point. Second,another major feature of radiation nephropathy, and it
also usually occurs earlier than the tubular injury. would antioxidants given at the time of the radiation
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Fig. 8. Schematic view of radiation nephrop-
athy. The earlier glomerular injury is predomi-
nantly endothelial, but mesangial injury also
is present. Fibrin and other mediators are gen-
erated, and this might lead to glomerular scar-
ring. The same mediators leave the glomerulus
via the tubule and, especially if there is subse-
quent tubular epithelial injury and death,
might contribute to interstitial scarring (Re-
produced by permission of the editor, Current
Radiation Oncology (Vol. 3), E. Arnold, Ltd,
London, 1997).
itself or shortly thereafter be helpful in preventing radia- and Tribondeau, who formulated their so-called law of
differential sensitivity based on proliferation rates.tion nephropathy?
Dr. Cohen: Those are important questions. Cellular You also asked whether antioxidants could be effec-
tive. Indeed, SH-group-containing compounds are effec-radio-biology teaches us that the most important injury
caused by ionizing radiation is injury to the DNA. Yet tive in preventing radiation injury, but they have to be
present at the time of the radiation. Unfortunately, mostin high enough doses, thousands of centigrays, one can
damage all parts of the cell: protein, membranes, en- are too toxic for clinical use. They may also protect
cancer cells. WR2721 is a classical radioprotector. Itzymes, and so on. To achieve cell killing at more custom-
ary doses, all you need to damage is DNA. A cell with works, and it has entered limited clinical use to reduce
normal tissue injury by some cancer chemotherapeuticdamaged DNA can function well enough if it does not
need to divide. The radiation-damaged DNA may ex- drugs. There is concern that this protective effect will
reduce the anti-cancer effect of the chemotherapy.press its genes, but the resulting proteins, even if abnor-
mal, will not rapidly cause cell malfunction. Persistent Dr. Harrington: What’s the “fluffy stuff” that you
showed us on the EM? Does that material have any rolenormal proteins, “left over” from before irradiation, will
enable the cell to continue its functions, at least for a in the development of the vascular lesion?
Dr. Cohen: We don’t know. It doesn’t stain routinelywhile. The most damaging effect will occur when the cell
attempts to divide, especially if there had been double- for fibrin, collagen, or amyloid. It’s probably some sort
of accumulation of plasma protein. From time to time,stranded DNA breaks. At mitosis, chromosomes won’t
go the right way or will reattach the wrong way, and the there are bits of platelets, red cells, and sometimes stain-
able iron within the “fluffy stuff” [11]. It’s not cryglobulinresulting cells will be highly abnormal and die. That
delayed death will occur as a function of proliferation or something else recognized.
Dr. Harrington: Do you see that same “fluffy stuff”rates. If the proliferation rate of a tissue is slow, cell
death will not occur very quickly. If the proliferation in other kinds of nephropathy?
Dr. Cohen: Yes, it is seen in TTP and to a limitedrate is fast, cell death will occur somewhat more quickly.
This phenomenon was recognized in 1906 by Bergonie´ degree in some cases of hemolytic-uremic syndrome.
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Dr. Nicolaos E. Madias (Executive Academic Dean, that irradiate the kidneys for autotransplantation see this
radiation nephropathy?Tufts University School of Medicine): Veno-occlusive dis-
Dr. Cohen: Dr. Levey, I’ll do my best to answer allease of the liver is also caused by endothelial injury but
three of your questions. Graft-versus-host (GVH) dis-occurs much earlier than radiation nephropathy. What
ease has been associated by more than one group withis our understanding of the determinants of susceptibility
a membranous nephropathy [77, 78]. Acute graft-versus-of the various endothelial beds to injury and of the tem-
host disease occurs within the first month or so afterporal pattern of the resulting organ dysfunction?
BMT, is determined largely by T-cells, and is not associ-Dr. Cohen: Not all endothelium is alike would be my
ated with glomerular disease. Chronic GVH occurs later,first response. The liver expresses injury not only as
often months later and sometimes longer, and appearsa function of the radiation but also as a function of
to be largely antibody mediated. That’s the GVH diseasechemotherapy. The same chemotherapy reaches the kid-
that is associated with the membranous changes. We’veneys and one can rationally ask why a similar reaction
never seen membranous nephropathy in our patientsdoes not commonly occur within the kidney. We do
with BMT nephropathy.know, however, as Shulman and colleagues described
You asked whether transplant glomerulopathy bearsin 1981 [15], that if you give enough cyclosporine to
any similarity to BMT nephropathy. We’ve seen oneirradiated BMT patients, a hemolytic-uremic syndrome
case of transplant glomerulopathy in which substantialoccurs rapidly, and within the same time frame as veno-
endothelial expansion looked a bit like these lesions. Iocclusive disease of the liver. This early syndrome oc-
have no doubt that the kidney can respond only in acurred within days or weeks of BMT, but it is less com-
certain number of ways, so that from time to time theremon now, probably as a result of partial renal shielding
can be overlapping morphologic appearances.and reduction in cyclosporine doses.
Is there proteinuria in BMT nephropathy? Yes, onDr. Madias: You highlighted endothelial injury as
the average 2 g/day. It generally is not nephrotic, but ita hallmark of radiation nephropathy. In various other
can be. There is a very broad spread, however, in thatsituations of endothelial dysfunction, changes in the ni-
value; some patients have several hundred milligramstric oxide system play a major role in the altered pheno-
and others have 5 g of urinary protein per day. Wetype. Is there any information on such changes in your
have not, however, seen high-grade proteinuria, 10 g andexperimental model and cell cultures?
more, as one might see in diabetic nephropathy.Dr. Cohen: We looked at urinary cyclic GMP as a
Last, you asked whether autologous transplant pro-marker for endothelial injury in this model and showed
grams using TBI have seen this syndrome. That wouldthat there is a significant decrement at nine weeks after
be a rare circumstance. Most autologous transplants are
17 Gy TBI [76]. We did not look earlier, however. This
done without using TBI. At our program, I have encoun-
decrement, only partially restored by the preventive use tered one such case in a man who underwent TBI-based
of captopril, suggests that it might not be critical in the autologous BMT for lymphoma. Ten years later, he has
sense that captopril can protect the kidney against radia- chronic renal failure and fulfills our criteria for BMT
tion injury without completely restoring urinary cyclic nephropathy.
GMP. We did do subsequent studies in which we corre- Dr. Andrew J. King (Division of Nephrology, New
lated the urinary cyclic GMP with nitrate and nitrite England Medical Center): The histologic appearance of
assays. We believe that our GMP studies did tell us the glomerular endothelial cells in the irradiated animals
something about the production of nitric oxide. brings to mind thrombotic microangiopathies. Is there
Dr. Andrew S. Levey (Chief, Division of Nephrology, evidence of systemic and local microangiopathy? Al-
New England Medical Center, Boston, Massachusetts): I though you made a strong point that this is not a nephri-
have three questions. First, do you think that any of the tis, I’m wondering whether in your animal model or in
radiation nephropathy after bone marrow transplanta- humans there is a renal inflammatory response early in
tion reflects an antigen-dependent immune response of the course of the disease.
donor bone marrow? Dr. Cohen: Is there evidence of microangiopathy?
Second, how similar are the glomerular changes that There most definitely is. I usually can detect it even in
you have attributed to radiation injury (the “fluffy” mate- the cases that do not look like HUS-TTP. There usually
rial on electron microscopy) to the glomerular changes are laboratory features that suggest microangiopathy: a
of “transplant glomerulopathy?” (Fig. 4) Transplant drop in blood platelets and rise in blood LDH levels. I
glomerulopathy is characterized by proteinuria. Do your look for those specifically to make this diagnosis. If they
patients have proteinuria? are not present, then the diagnosis is in question. I was
Third, some bone marrow transplant programs use total- able to show that the increase of the LDH and the degree
body irradiation during autotransplantation, in which of the platelet count drop related directly to the recipro-
cal slope of plasma creatinine [11].there is no graft-versus-host disease. Do the programs
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As for inflammation, the histology of experimental porcine radiation nephropathy model. There was attenu-
ation of radiation-induced early hemodynamic changesradiation nephropathy can include some interstitial mono-
nuclear cell infiltrates. These are not prominent, and they by use of captopril in porcine radiation nephropathy [44].
Two other groups have used ACE inhibitors in differentdo not precede the rather more impressive glomerular
changes. varieties of rats undergoing experimental renal irradia-
tion. I believe that we can extrapolate this informationDr. Klemens B. Meyer (Division of Nephrology, New
England Medical Center): Do you think that the captopril to humans.
Dr. Sasu: You mentioned that most antioxidants stud-effect is specific to this situation, or is it just that ACE
inhibitors are good for renal disease? ied in experimental conditions are toxic when used in
humans. Are you aware of any relevant experimentalDr. Cohen: I don’t think that captopril is the specific
antidote. As I said, enalapril works almost equally as data or ongoing clinical trials involving the antioxidant
pentoxifylline, which has proven to be a good antioxidantwell. The success with the AT1 receptor antagonist L-
158,809 suggests that angiotensin II is important. Our in experimental conditions and is also known to be less
toxic for human use?work using Ang II infusion supports that conclusion. It
remains possible that if we can find an effective antihy- Dr. Cohen: The antioxidant pentoxiphylline has been
used by Ward and colleagues in experimental radiationpertensive agent in our model other than captopril or
an Ang II blocker, we’ll be able to slow progression. pneumonitis and has some beneficial effect. We have
not tried it in radiation nephropathy. But remember thatThe problem is that we have not found any other agent.
Verapamil is not effective [42]. Our rats would not drink all discussion of antioxidants has to take into account the
radiochemistry of ionizing radiation. Creation of oxygenwater containing propranolol; alpha-methyldopa was in-
effective, as was hydrochlorothiazide. Clinically, I be- radicals takes place within the first milliseconds after
irradiation. An agent that prevents that has to be presentlieve that the lower the blood pressure, the better the
outcome. I think that is a reasonable statement now for at that time. One could argue that in subsequent stages,
the tissue itself undergoes oxidative injury, perhaps be-most renal disease. Ritz and colleagues have shown that
the regression line of antihypertensive effect versus anti- cause neutrophils arrive there and begin damaging the
tissue. Their bad effects might be appropriately antago-proteinuric effect of ACE inhibitors and non-ACE inhib-
itors appears to converge once the blood pressure is low nized by the appropriate agent. I can’t rule that out.
However, pentoxifylline, used preventively in humanenough [79].
Dr. Meyer: Do you think that the experience of hu- BMT in one study, did not reduce transplant-related
toxicities [80].mans who are exposed to environmental radiation is at
all relevant? I’m thinking of people exposed to atomic Dr. Madias: In a number of experimental models of
renal disease, ACE inhibitors decrease expression ofbomb and nuclear power plant explosions. What happens
to their kidneys? TGF-b in association with functional and histologic im-
provement. Do you have data on the effects of ACEDr. Cohen: The LD50 within 60 days of total-body
irradiation without BMT is about 500 centigray. This inhibitors on TGF-b expression in your model?
Dr. Cohen: In collaboration with Dr. Elias Lianos,was the approximate amount of radiation at one mile
from the Hiroshima hypocenter. Five hundred centigray we studied the preventive use of L-158,809 and showed
that the enhanced TGF-b1 expression in a 20 Gy localis not really enough, even in a single fraction, to cause
substantial renal injury, at least for a few years. What kidney-irradiation model could be completely elimi-
nated by the use of this angiotensin II blocker [81]. Iwill happen within 10 to 21 days of 500 cGy TBI is a
high risk of bone marrow failure and death. If you follow should caution, however, that the TGF-b1 expression in
this model occurs a little later than the critical intervalthe survivors of 500 cGy TBI for 10 years, you might
find some low-grade renal injury. At higher doses, death that I mentioned; it only begins to be significant at about
50 to 60 days. Whether that reduction in TGF-b1 expres-due to gastrointestinal or bone marrow failure would
occur before renal failure would have time to develop. sion is critical is not established. It could merely be an-
other way of documenting lesser injury. As for ACEDr. Sebastian Sasu (Nephrology Fellow, Division of
Nephrology, New England Medical Center): The ACE inhibitors, Fogo’s group showed a beneficial effect of
captopril in a local kidney model of radiation nephropa-inhibitor therapy data that you presented focused mostly
on studies done in the rat. As you pointed out, different thy with an insignificant effect on TBF-b1 [53].
Dr. Harrington: We have seen several patients fol-experimental models, that is, pigs and mice, present with
slightly different morphologies. In your experience, are lowing bone marrow transplant with a disproportionate
anemia. Is the disproportionate anemia a direct effectthe data from the ACE inhibitor therapy studies consis-
tent between the two models? Do you think these data of the radiation nephropathy, or could the concurrent
use of enalapril have any effect on that finding?are a good indicator of what happens in humans?
Dr. Cohen: ACE inhibitors have been used in the Dr. Cohen: Synthesis of reported data on classical
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radiation nephropathy shows a similar relationship of Dr. Cohen: I followed this patient for almost a decade.
The requirement for chronic dialysis has been a setbackanemia to azotemia. That is, subjects with classical radia-
tion nephropathy have a greater-than-expected degree for her. She has other complications of BMT or in associ-
ation with BMT, including bone disease. She is, however,of anemia for their degree of azotemia, as BUN [22].
These data were all reported before 1978, before ACE reasonably stable on hemodialysis. Renal transplanta-
tion would be just one more procedure in which theinhibitors were available for clinical use. Also, our data
for the relationship of anemia versus azotemia in BMT outcome can’t be predicted. Overall, I believe that such
patients are suitable candidates for renal transplantationnephropathy were derived at the time of diagnosis of
BMT nephropathy, which is a time when a patient would from the donor who provided the bone marrow, but
obviously only after careful and full evaluation.typically not be taking ACE inhibitors. Thus, the dispro-
portionately severe anemia appears to be caused by the
radiation nephropathy itself. ACKNOWLEDGMENTS
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Recently, increased glomerular permeability has been
plausible apoptotic pathways, such as the Fas/Fas ligand
found within one hour of renal irradiation in rats (ab-
system, were explored?
stract; Sharma M, Sharma R, McCarthy ET, Ge XL, Fish
Dr. Cohen: That is an important issue. We don’t know
B, Savin VJ, Cohen EP, Moulder JE: Early detection of
exactly why tubular cell death occurs after irradiation.
radiation-induced glomerular injury by albumin perme-
We don’t understand the tubular proliferation either.
ability assay. J Am Soc Nephrol 10:115A, 1999). This
Two groups have found that apoptosis occurs in renal
early response does not seem to depend on radiation-
epithelial cells within 24 hours of 5 or 6 Gy total body
induced cell death. However, its significance for laterirradiation [73, 82]. Apoptosis clearly could play a role
development of renal failure is uncertain, because it doesin the early response and might promote the later prolif-
not correlate with proteinuria.erative response to renal irradiation. The Fas/Fas ligand
system has not been looked at, to my knowledge.
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